Cargando…

The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT)

We conducted a prospective study of 312 patients (194 with multiple myeloma, 118 with lymphomas) receiving high-dose conditioning chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT). Polymorphisms of MBL2 and MASP2 genes were investigated and serial measurements of serum...

Descripción completa

Detalles Bibliográficos
Autores principales: Świerzko, Anna S., Michalski, Mateusz, Sokołowska, Anna, Nowicki, Mateusz, Eppa, Łukasz, Szala-Poździej, Agnieszka, Mitrus, Iwona, Szmigielska-Kapłon, Anna, Sobczyk-Kruszelnicka, Małgorzata, Michalak, Katarzyna, Gołos, Aleksandra, Wierzbowska, Agnieszka, Giebel, Sebastian, Jamroziak, Krzysztof, Kowalski, Marek L., Brzezińska, Olga, Thiel, Steffen, Jensenius, Jens C., Kasperkiewicz, Katarzyna, Cedzyński, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158352/
https://www.ncbi.nlm.nih.gov/pubmed/30294330
http://dx.doi.org/10.3389/fimmu.2018.02153
_version_ 1783358413446578176
author Świerzko, Anna S.
Michalski, Mateusz
Sokołowska, Anna
Nowicki, Mateusz
Eppa, Łukasz
Szala-Poździej, Agnieszka
Mitrus, Iwona
Szmigielska-Kapłon, Anna
Sobczyk-Kruszelnicka, Małgorzata
Michalak, Katarzyna
Gołos, Aleksandra
Wierzbowska, Agnieszka
Giebel, Sebastian
Jamroziak, Krzysztof
Kowalski, Marek L.
Brzezińska, Olga
Thiel, Steffen
Jensenius, Jens C.
Kasperkiewicz, Katarzyna
Cedzyński, Maciej
author_facet Świerzko, Anna S.
Michalski, Mateusz
Sokołowska, Anna
Nowicki, Mateusz
Eppa, Łukasz
Szala-Poździej, Agnieszka
Mitrus, Iwona
Szmigielska-Kapłon, Anna
Sobczyk-Kruszelnicka, Małgorzata
Michalak, Katarzyna
Gołos, Aleksandra
Wierzbowska, Agnieszka
Giebel, Sebastian
Jamroziak, Krzysztof
Kowalski, Marek L.
Brzezińska, Olga
Thiel, Steffen
Jensenius, Jens C.
Kasperkiewicz, Katarzyna
Cedzyński, Maciej
author_sort Świerzko, Anna S.
collection PubMed
description We conducted a prospective study of 312 patients (194 with multiple myeloma, 118 with lymphomas) receiving high-dose conditioning chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT). Polymorphisms of MBL2 and MASP2 genes were investigated and serial measurements of serum concentrations of mannose-binding lectin (MBL), CL-LK collectin and MASP-2 as well as activities of MBL-MASP-1 and MBL-MASP-2 complex were made. Serum samples were taken before conditioning chemotherapy, before HSCT and once weekly after (totally 4-5 samples); in minority of subjects also 1 and/or 3 months post transplantation. The results were compared with data from 267 healthy controls and analyzed in relation to clinical data to explore possible associations with cancer and with chemotherapy-induced medical complications. We found a higher frequency of MBL deficiency-associated genotypes (LXA/O or O/O) among multiple myeloma patients compared with controls. It was however not associated with hospital infections or post-HSCT recovery of leukocytes, but seemed to be associated with the most severe infections during follow-up. Paradoxically, high MBL serum levels were a risk factor for prolonged fever and some infections. The first possible association of MBL2 gene 3′-untranslated region polymorphism with cancer (lymphoma) in Caucasians was noted. Heterozygosity for MASP2 gene +359 A>G mutation was relatively frequent in lymphoma patients who experienced bacteremia during hospital stay. The median concentration of CL-LK was higher in myeloma patients compared with healthy subjects. Chemotherapy induced marked increases in serum MBL and MASP-2 concentrations, prolonged for several weeks and relatively slighter decline in CL-LK level within 1 week. Conflicting findings on the influence of MBL on infections following chemotherapy of myeloma and lymphoma have been reported. Here we found no evidence for an association between MBL deficiency and infection during the short period of neutropenia following conditioning treatment before HSCT. However, we noted a possible protective effect of MBL during follow-up, and suspected that to be fully effective when able to act in combination with phagocytic cells after their recovery.
format Online
Article
Text
id pubmed-6158352
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61583522018-10-05 The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT) Świerzko, Anna S. Michalski, Mateusz Sokołowska, Anna Nowicki, Mateusz Eppa, Łukasz Szala-Poździej, Agnieszka Mitrus, Iwona Szmigielska-Kapłon, Anna Sobczyk-Kruszelnicka, Małgorzata Michalak, Katarzyna Gołos, Aleksandra Wierzbowska, Agnieszka Giebel, Sebastian Jamroziak, Krzysztof Kowalski, Marek L. Brzezińska, Olga Thiel, Steffen Jensenius, Jens C. Kasperkiewicz, Katarzyna Cedzyński, Maciej Front Immunol Immunology We conducted a prospective study of 312 patients (194 with multiple myeloma, 118 with lymphomas) receiving high-dose conditioning chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT). Polymorphisms of MBL2 and MASP2 genes were investigated and serial measurements of serum concentrations of mannose-binding lectin (MBL), CL-LK collectin and MASP-2 as well as activities of MBL-MASP-1 and MBL-MASP-2 complex were made. Serum samples were taken before conditioning chemotherapy, before HSCT and once weekly after (totally 4-5 samples); in minority of subjects also 1 and/or 3 months post transplantation. The results were compared with data from 267 healthy controls and analyzed in relation to clinical data to explore possible associations with cancer and with chemotherapy-induced medical complications. We found a higher frequency of MBL deficiency-associated genotypes (LXA/O or O/O) among multiple myeloma patients compared with controls. It was however not associated with hospital infections or post-HSCT recovery of leukocytes, but seemed to be associated with the most severe infections during follow-up. Paradoxically, high MBL serum levels were a risk factor for prolonged fever and some infections. The first possible association of MBL2 gene 3′-untranslated region polymorphism with cancer (lymphoma) in Caucasians was noted. Heterozygosity for MASP2 gene +359 A>G mutation was relatively frequent in lymphoma patients who experienced bacteremia during hospital stay. The median concentration of CL-LK was higher in myeloma patients compared with healthy subjects. Chemotherapy induced marked increases in serum MBL and MASP-2 concentrations, prolonged for several weeks and relatively slighter decline in CL-LK level within 1 week. Conflicting findings on the influence of MBL on infections following chemotherapy of myeloma and lymphoma have been reported. Here we found no evidence for an association between MBL deficiency and infection during the short period of neutropenia following conditioning treatment before HSCT. However, we noted a possible protective effect of MBL during follow-up, and suspected that to be fully effective when able to act in combination with phagocytic cells after their recovery. Frontiers Media S.A. 2018-09-20 /pmc/articles/PMC6158352/ /pubmed/30294330 http://dx.doi.org/10.3389/fimmu.2018.02153 Text en Copyright © 2018 Świerzko, Michalski, Sokołowska, Nowicki, Eppa, Szala-Poździej, Mitrus, Szmigielska-Kapłon, Sobczyk-Kruszelnicka, Michalak, Gołos, Wierzbowska, Giebel, Jamroziak, Kowalski, Brzezińska, Thiel, Jensenius, Kasperkiewicz and Cedzyński. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Świerzko, Anna S.
Michalski, Mateusz
Sokołowska, Anna
Nowicki, Mateusz
Eppa, Łukasz
Szala-Poździej, Agnieszka
Mitrus, Iwona
Szmigielska-Kapłon, Anna
Sobczyk-Kruszelnicka, Małgorzata
Michalak, Katarzyna
Gołos, Aleksandra
Wierzbowska, Agnieszka
Giebel, Sebastian
Jamroziak, Krzysztof
Kowalski, Marek L.
Brzezińska, Olga
Thiel, Steffen
Jensenius, Jens C.
Kasperkiewicz, Katarzyna
Cedzyński, Maciej
The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT)
title The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT)
title_full The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT)
title_fullStr The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT)
title_full_unstemmed The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT)
title_short The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT)
title_sort role of complement activating collectins and associated serine proteases in patients with hematological malignancies, receiving high-dose chemotherapy, and autologous hematopoietic stem cell transplantations (auto-hsct)
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158352/
https://www.ncbi.nlm.nih.gov/pubmed/30294330
http://dx.doi.org/10.3389/fimmu.2018.02153
work_keys_str_mv AT swierzkoannas theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT michalskimateusz theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT sokołowskaanna theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT nowickimateusz theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT eppałukasz theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT szalapozdziejagnieszka theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT mitrusiwona theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT szmigielskakapłonanna theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT sobczykkruszelnickamałgorzata theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT michalakkatarzyna theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT gołosaleksandra theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT wierzbowskaagnieszka theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT giebelsebastian theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT jamroziakkrzysztof theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT kowalskimarekl theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT brzezinskaolga theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT thielsteffen theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT jenseniusjensc theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT kasperkiewiczkatarzyna theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT cedzynskimaciej theroleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT swierzkoannas roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT michalskimateusz roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT sokołowskaanna roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT nowickimateusz roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT eppałukasz roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT szalapozdziejagnieszka roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT mitrusiwona roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT szmigielskakapłonanna roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT sobczykkruszelnickamałgorzata roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT michalakkatarzyna roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT gołosaleksandra roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT wierzbowskaagnieszka roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT giebelsebastian roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT jamroziakkrzysztof roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT kowalskimarekl roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT brzezinskaolga roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT thielsteffen roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT jenseniusjensc roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT kasperkiewiczkatarzyna roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct
AT cedzynskimaciej roleofcomplementactivatingcollectinsandassociatedserineproteasesinpatientswithhematologicalmalignanciesreceivinghighdosechemotherapyandautologoushematopoieticstemcelltransplantationsautohsct